Acta Pharmaceutica Sinica B (Jul 2024)

LncRNA ZFPM2-AS1 promotes phyllodes tumor progression by binding to CDC42 and inhibiting STAT1 activation

  • Shishi He,
  • Guowei Huang,
  • Rong Lei,
  • Rurong Jia,
  • Zhanghai He,
  • Jiewen Chen,
  • Hongyan Huang,
  • Zixian Huang,
  • Ailifeire Yilihamu,
  • Xun Li,
  • Zilin Zhuang,
  • Mengjia Han,
  • Xueman Chen,
  • Di Huang,
  • Yan Nie

Journal volume & issue
Vol. 14, no. 7
pp. 2942 – 2958

Abstract

Read online

Breast phyllodes tumor (PT) is a rare fibroepithelial neoplasm with potential malignant behavior. Long non-coding RNAs (lncRNAs) play multifaceted roles in various cancers, but their involvement in breast PT remains largely unexplored. In this study, microarray was leveraged for the first time to investigate the role of lncRNA in PT. We identified lncRNA ZFPM2-AS1 was significantly upregulated in malignant PT, and its overexpression endowed PT with high tumor grade and adverse prognosis. Furthermore, we elucidated that ZFPM2-AS1 promotes the proliferation, migration, and invasion of malignant PT in vitro. Targeting ZFPM2-AS1 through nanomaterial-mediated siRNA delivery in patient-derived xenograft (PDX) model could effectively inhibit tumor progression in vivo. Mechanistically, our findings showed that ZFPM2-AS1 is competitively bound to CDC42, inhibiting ACK1 and STAT1 activation, thereby launching the transcription of TNFRSF19. In conclusion, our study provides evidence that ZFPM2-AS1 plays a pivotal role in the pathogenesis of breast PT, and suggests that ZFPM2-AS1 could serve as a prognostic indicator for patients with PT as well as a promising novel therapeutic target.

Keywords